- Home
- LHX vs TAK Comparison
LHX vs TAK Comparison
Compare LHX & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LHX
- TAK
- Stock Information
- Founded
- LHX 1895
- TAK 1781
- Country
- LHX United States
- TAK Japan
- Employees
- LHX N/A
- TAK N/A
- Industry
- LHX Industrial Machinery/Components
- TAK Biotechnology: Pharmaceutical Preparations
- Sector
- LHX Industrials
- TAK Health Care
- Exchange
- LHX Nasdaq
- TAK Nasdaq
- Market Cap
- LHX 51.9B
- TAK 47.3B
- IPO Year
- LHX N/A
- TAK N/A
- Fundamental
- Price
- LHX $281.94
- TAK $15.08
- Analyst Decision
- LHX Buy
- TAK
- Analyst Count
- LHX 18
- TAK 0
- Target Price
- LHX $278.94
- TAK N/A
- AVG Volume (30 Days)
- LHX 990.6K
- TAK 3.1M
- Earning Date
- LHX 10-23-2025
- TAK 10-30-2025
- Dividend Yield
- LHX 1.70%
- TAK 3.60%
- EPS Growth
- LHX 43.44
- TAK N/A
- EPS
- LHX 8.95
- TAK 0.59
- Revenue
- LHX $21,373,000,000.00
- TAK $31,053,301,865.00
- Revenue This Year
- LHX $3.09
- TAK $0.40
- Revenue Next Year
- LHX $5.78
- TAK $0.83
- P/E Ratio
- LHX $31.51
- TAK $25.50
- Revenue Growth
- LHX 2.93
- TAK 1.52
- 52 Week Low
- LHX $193.09
- TAK $12.80
- 52 Week High
- LHX $282.22
- TAK $15.69
- Technical
- Relative Strength Index (RSI)
- LHX 65.46
- TAK 50.98
- Support Level
- LHX $268.60
- TAK $14.87
- Resistance Level
- LHX $274.70
- TAK $15.38
- Average True Range (ATR)
- LHX 3.89
- TAK 0.18
- MACD
- LHX 0.27
- TAK -0.02
- Stochastic Oscillator
- LHX 97.94
- TAK 32.97
About LHX L3Harris Technologies Inc.
In addition to its legacy software-defined radio franchise, L3Harris Technologies has through a series of acquisitions established franchises producing uncrewed aerial vehicles, sensors, avionics, space-based systems, missiles, and solid rocket motors. It also adapts civilian aircraft for military use and provides military and commercial training services, and maintains the US Federal Aviation Administration's communications infrastructure.
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.